Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. - Wikidata - awgldk - TriplyDB

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

http://www.wikidata.org/entity/Q37354438

about

Clinical manifestations and management of Gaucher disease An overview of Compassionate Use Programs in the European Union member states Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment Gaucher disease in a family from Maranhão Hemorrhagic aspects of Gaucher disease.Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.Gaucher disease and cancer: concept and controversy.Gaucher disease and the synucleinopathies: refining the relationship.Generation of a Chinese hamster ovary cell line producing recombinant human glucocerebrosidase.Echocardiographic Assessment of Left Ventricular Function in Type 1 Gaucher's Disease.

P2860

Q26775747-A81863D6-0D6C-418C-A2B3-C369D76A21DB Q28071010-467CC1CF-79BF-443F-8365-CACF8D5CCD86 Q33403298-C4A672BE-D9A8-465B-95EA-53661EE5FF5B Q33418130-FF2D821B-1FBF-4DA1-A487-C4A88A84A167 Q33418647-F6A79E4B-DE4C-47A0-B580-0D0EDF0DF0C6 Q33692023-4DA6151A-5FF2-4CFF-8002-4030FEEEA675 Q35806919-63EF776B-A38F-481B-BA70-F2639C4BF510 Q36556379-CC94CF59-0BCC-4224-9916-497A69464A6F Q37400927-EB5C294A-3BE5-4421-A3B8-7DE539316B86 Q37901381-8F73AE4D-CA6D-4E82-A072-947EE92C66CB Q37979978-17F0B7B7-23E9-4329-971E-C24945C5D6AC Q39254681-24ABD33C-6BF8-45C0-AEB1-74F6937B876B Q42615121-B291E204-250C-4F6D-AB5C-955C1C93751C

P2860

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

http://www.wikidata.org/entity/Q37354438

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

@en

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

@nl

type

label

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

@en

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

@nl

prefLabel

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

@en

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

@nl

P1433

Q37354438-61F572D1-C897-40FC-9F98-112B9AC39970

P1476

Q37354438-F5F376F9-20AB-400F-B9E4-AF58579C9A75

P2093

Q37354438-1BE7858C-261E-4B58-89FD-09DDB5DFC778

Q37354438-89DA1541-FD82-4B82-8049-2A0E9363BC04

P2860

Q37354438-0732B5C0-DA99-46BB-8776-09DCC87B0D8F

Q37354438-088863F4-5F7A-45F8-AB92-82AA6F7D31B2

Q37354438-0C5E750A-35E5-40C2-80FE-07157BD3BCCD

Q37354438-1347871F-DC5F-4AB8-9BC8-50D621196743

Q37354438-164B1A3B-63C6-484E-B9D4-7D5B668E227C

Q37354438-1EB0EB06-95D7-4277-A19D-5F805793EF03

Q37354438-21A42CB0-7A6C-4AA4-ABB9-596BFD69794F

Q37354438-22E4A457-0AD8-421B-8CE4-9A24B02AFC0D

Q37354438-23A26D8E-D824-482E-8BBE-2F8AE3BFCB07

Q37354438-268A7056-5BE6-4F1E-843B-09F2F2FEE4EA

P304

Q37354438-449B978E-092D-461A-B546-B3BFA7FDABD3

P31

Q37354438-FFBF146C-152E-47F0-B3C1-965567277852

P356

Q37354438-C8B5377F-F4E6-4675-9DC2-6ABD13F0C806

P478

Q37354438-B4E5C1A0-E542-4560-B44E-2F528EB555E0

P577

Q37354438-3DD9326C-3B18-4A89-A3CC-02778CF56E4D

P5875

Q37354438-41582F3C-3875-401F-9E0C-2A2390909E79

P698

Q37354438-D46BBCCB-B649-4C7B-BE5D-EEEBE0840AAF

P932

Q37354438-E5F1C989-01B3-4036-95AE-3563EDE7118F

P356

P1433

Biologics: Targets and Therapy

P1476

Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

@en

P2093

Ari Zimran

http://www.w3.org/2001/XMLSchema#string

Deborah Elstein

http://www.w3.org/2001/XMLSchema#string

P2860

A plant-derived recombinant human glucocerebrosidase enzyme--a preclinical and phase I investigation

Life expectancy in Gaucher disease type 1

The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement

Glucocerebrosidase mutations in subjects with parkinsonism

The long-term international safety experience of imiglucerase therapy for Gaucher disease

Randomized, controlled trial of miglustat in Gaucher's disease type 3.

Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy.

Anaphylactoid reaction to imiglucerase, but not to alglucerase, in a type I Gaucher patient.

Withdrawal of enzyme replacement therapy in Gaucher's disease.

The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease.

P304

407-417

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BTT.2009.3497

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26831461

http://www.w3.org/2001/XMLSchema#string

P698

19774208

http://www.w3.org/2001/XMLSchema#string

P932

2747339

http://www.w3.org/2001/XMLSchema#string